Avantor (AVTR)
(Delayed Data from NYSE)
$25.60 USD
-0.90 (-3.40%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $25.60 0.00 (0.00%) 7:04 PM ET
3-Hold of 5 3
B Value B Growth F Momentum C VGM
Avantor, Inc. (AVTR) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$27.71 | $31.00 | $22.00 | 4.57% |
Price Target
Based on short-term price targets offered by 17 analysts, the average price target for Avantor, Inc. comes to $27.71. The forecasts range from a low of $22.00 to a high of $31.00. The average price target represents an increase of 4.57% from the last closing price of $26.50.
Analyst Price Targets (17)
Broker Rating
Avantor, Inc. currently has an average brokerage recommendation (ABR) of 1.66 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 19 brokerage firms. The current ABR compares to an ABR of 1.55 a month ago based on 19 recommendations.
Of the 19 recommendations deriving the current ABR, 11 are Strong Buy and three are Buy. Strong Buy and Buy respectively account for 57.89% and 15.79% of all recommendations. A month ago, Strong Buy made up 63.16%, while Buy represented 15.79%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 11 | 11 | 12 | 12 | 12 |
Buy | 3 | 3 | 3 | 3 | 3 |
Hold | 5 | 5 | 4 | 4 | 4 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.66 | 1.66 | 1.55 | 1.55 | 1.55 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/29/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
7/29/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
7/29/2024 | Robert W. Baird & Co. | Catherine W Schulte | Strong Buy | Strong Buy |
7/29/2024 | Cowen & Co. | Daniel Brennan | Strong Buy | Strong Buy |
7/29/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
7/10/2024 | Not Identified | Not Identified | Strong Buy | Hold |
6/3/2024 | Not Identified | Not Identified | Not Available | Strong Buy |
4/29/2024 | William Blair | Matt Larew | Hold | Hold |
4/29/2024 | Raymond James | Andrew Cooper | Moderate Buy | Moderate Buy |
4/4/2024 | Evercore Partners | Vijay Kumar | Strong Buy | Strong Buy |
2/15/2024 | UBS | Joshua Spector | Not Available | Strong Buy |
12/13/2023 | Not Identified | Not Identified | Not Available | Hold |
12/7/2023 | Goldman Sachs | Matthew Sykes | Strong Buy | Strong Buy |
10/27/2023 | KeyBanc Capital Markets | Paul Knight | Strong Buy | Strong Buy |
9/28/2023 | Not Identified | Not Identified | Not Available | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.66 |
ABR (Last week) | 1.66 |
# of Recs in ABR | 19 |
Average Target Price | $27.71 |
LT Growth Rate | 9.70% |
Industry | Medical Services |
Industry Rank by ABR | 101 of 253 |
Current Quarter EPS Est: | 0.26 |